GSK Response to CHOICE Media Release

GSK has previously provided detailed product information and clinical studies to CHOICE and would like to respond to some of the allegations made in the CHOICE media release – Pain Pills Hurting The Hip Pocket.

GSK has previously provided detailed product information and clinical studies to CHOICE and would like to respond to some of the allegations made in the CHOICE media release – Pain Pills Hurting The Hip Pocket.

Panadol Osteo and Panadol Back and Neck Long Lasting both have the same product formulation; however they manage different pain states. Panadol Osteo is prescribed by doctors to manage the longer-term pain associated with osteoarthritis and is listed on the PBS and the price is governed by a government agreement. Panadol Back & Neck Long Lasting is designed for short term use to manage acute muscular pain and is available in pharmacies.

Panadol with Optizorb technology uses a unique combination of alginic acid and calcium carbonate to speed tablet disintegration and is clinically proven to be absorbed faster than regular Panadol tablets.

As a market leader, GSK continue to provide a range of pain relief products that are based upon science, supported by extensive research and to best suit the differing needs of our consumers.

Further information relating to our range of Panadol products can be found here www.panadol.com.au

ALWAYS READ THE LABEL. Use only as directed. For the temporary relief of pain and fever. Incorrect use could be harmful. Consult your healthcare professional if symptoms persist.
Panadol is a registered trade mark of the GSK group of companies.

-ENDS-

For further information contact:

Joanne Clark
Tel: +61 2 9684 0741
Mobile: +61 407 829 209
Email:joanne.v.clark@gsk.com

Lisa Maguire
Tel: +61 3 9721 6637
Mobile: +61 449 950 745
Email:lisa.a.maguire@gsk.com

Follow us on Twitter -@GSK_AU